People · Operator
Named in public records as an officer, director or promoter · active 2011–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2021 |
| Enobia Pharma Corp | — | Biotechnology | Series C | $100.0M | $819.2M | 2011 |
| Tribute Pharmaceuticals Canada Inc. | — | Pharmaceuticals | Series C | $92.1M | $2.6B | 2016 |
| Aralez Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $75.0M | $2.6B | 2016 |
Eric L. Trachtenberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric L. Trachtenberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew I. Koven | 3 | 4 |
| Scott J. Charles | 2 | 2 |
| Robert Langer | 1 | 36 |
| Kevin Bitterman | 1 | 15 |
| Jonathan Silverstein | 1 | 10 |
| Robert Harris | 1 | 9 |
| Robert Tepper | 1 | 7 |
| David Bonita | 1 | 6 |
| DAVID LAZAR | 1 | 5 |
| ROBERT PAULL | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
| Brendan Purdy | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| PETER COUROSSI | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Robert L. Harris | 1 | 4 |
| Thomas Schuetz | 1 | 4 |
| JUSTIN HANES | 1 | 3 |
| Greg Grunberg | 1 | 3 |
| Gregory D. Perry | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.